解放军医学院学报2017，Vol.38Issue(5)：423-425,3.DOI:10.3969/j.issn.2095-5227.2017.05.010
替格瑞洛在老年冠脉病变介入治疗中的疗效及安全性分析
Clinical efficacy and safety of ticagrelor in elderly patients with complex coronary disease undergoing primary percutaneous coronary intervention
柳杨 1李运田 1王小冬 1武效宏 1李巍 1杜大勇1
作者信息
- 1. 解放军第305医院 心脏中心,北京 100017
- 折叠
摘要
Abstract
Objective To analyze the clinical efficacy and safety of ticagrelor in aged patients with complex coronary disease undergoing primary percutaneous coronary intervention(PCI). Methods Eighty-two elderly patients ( > 65 years old) with complex coronary disease undergoing primary PCI in our hospital from Jan. 2013 to Dec. 2014 were included. The patients were randomly divided into clopidogrel group (n=40) and ticagrelor group (n=42). A loading dose of aspirin 300 mg + clopidogrel 600 mg versus aspirin 300 mg + ticagrelor 180 mg were prescribed respectively for the two groups, followed by aspirin 100 mg/d + clopidogre 175 mg/d versus aspirin 100 mg/d + ticagrelor 180 mg/d for maintenance dose from the next day. All the patients were followed up for 12 months. The incidences of cardiovascular ischemic events and major bleeding events were recorded and compared. Results after a 12-month follow-up, incidences of the major adverse cardiovascular events and recurrent angina in ticagrelor group were lower than those of clopidogrel group (0 vs 10%, P < 0.05; 4.8% vs 20.0%. P < 0.05). Dyspnea were more commonly seen in ticagrelor group compared with clopidogrel group (14.3% vs 0, P < 0.05), while no significant difference were shown in severe hemorrhage and stent thrombosis between the two groups. Conclusion In elderly patients with complex coronary disease treated by PCI, ticagrelor canreduce major adverse cardiovascular events compared with clopidogrel. Though a common adverse reaction as dyspnea occurs in ticagrelor group, risk of bleeding doen't increase showing its safety.关键词
替格瑞洛/老年人/冠心病/介入治疗Key words
ticagrelor/aged/coronary disease/interventional therapy分类
医药卫生引用本文复制引用
柳杨,李运田,王小冬,武效宏,李巍,杜大勇..替格瑞洛在老年冠脉病变介入治疗中的疗效及安全性分析[J].解放军医学院学报,2017,38(5):423-425,3.
